Basic Pharma operates a fully GMP certified facility at the Brightlands Chemelot Research Campus in Geleen, The Netherlands. Basic Pharma has established a good reputation in the development, licensing and manufacturing of pharmaceutical liquids (including pre-filled syringes and vials) and semi-solids. Our expertise and facilities enable us to deliver a full package to the Pharmaceutical, Biotech and Medical Device industry.

Basic Pharma

Basic Pharma

Burgemeester Lemmensstraat 352
P.O. Box 1124
6160 BC Geleen
The Netherlands

+31 (0)88 255 40 10
info@basicpharma.nl
basicpharma.nl

Basic Pharma, an advanced and independent group of pharmaceutical companies. We are primarily engaged in developing, licensing, manufacturing and commercialisation of pharmaceutical and biopharmaceutical products and deliver a full package of services to the Pharmaceutical, Biotech and Medical Device industry.

The Basic Pharma group comprises the following entities:

- **Basic Pharma Manufacturing**, manufacturing of registered and non-registered pharmaceutical products, investigational medicinal products and laboratory services.
- **Basic Pharma Technologies**, (co-)development and licensing of pharmaceutical and biopharmaceutical products.
- **Interdos**, services and consultancy, in the field of regulatory, pharmacovigilance, clinical and quality, for pharmaceutical, biotech and medical device companies.

Internal synergy drives innovation!

The group combines its knowledge, skills and facilities from product development to commercialisation. Covering all the steps from product development, licensing, upscaling to manufacturing allows us to gain a lot of expertise and know how, enabling us to innovate efficiently and effectively. We, and our partners, benefit from our innovative strength in co-development projects, leading to intensive cooperation and partnerships.

Basic Pharma Manufacturing

Our manufacturing division executes operations of production, quality control (laboratory), quality assurance, supply chain and sales. Its facilities include certified cleanrooms in classes B, C and D, where pharmaceutical products and investigational medicinal product are prepared by batch processing, from compounding to finishing and filling into primary packed products. In our GMP controlled clean rooms, we are able to provide a wide range of services with respect to Investigational Medicinal Products, such as (aseptic) fill and finish of solutions for injections including cytotoxic compounds, blinding of study medication, randomization, packaging and labelling of clinical trial medication etc.
Basic Pharma Manufacturing also possesses the relevant permits for processing and manufacturing. The production lines are equipped with state of the art machinery for processing of liquids, suspensions, creams and ointments into finished pharmaceutical products, which are generally commercialised under private label. We are able to manufacture sterile and non-sterile products (including pre-filled syringes and vials) and to handle high potency compounds.

Consecutively the intermediate primary packed products are being labelled and packed in adjacent facilities on automated labelling and packing lines. In preparation to the new European regulations regarding serialisation, applicable as of February 2019, our company made an early start allowing ourselves to be ready ahead of schedule to meet the new requirements.

Basic Pharma Technologies

Our development division runs product development projects from generic to innovative medicines. Multiple development projects are being coordinated and executed at any given time, including co-financed projects. The successful completion of such projects results in product registrations in various countries. The activities of Basic Pharma Technologies aim to grow the current product pipeline. In this process Interdos submits product dossiers for filing and registration in several markets, while our manufacturing division handles production and distribution. With this comprehensive service package, the group's activities cover the entire chain from product development, licensing and production up to and including sales and distribution.

In 2017 the 'SKiN-Huid' programme was launched, an early development project with several partners to develop and manufacture a drug to fight skin tumours. The programme is subsidised by the European Union (Interreg Flanders-Netherlands), with additional sponsorship from the Province of Limburg and the Dutch Ministry of Economic Affairs.

Interdos

The group's consultancy firm Interdos provides tailor-made services to a wide range of customers and business partners in the pharmaceutical supply chain. This includes the internal clients, Basic Pharma Manufacturing and Basic Pharma Technologies, as well as external (international) clients and partners. More information about Interdos: www.interdos.nl